Skip to main content
ARS Home » Northeast Area » Orient Point, New York » Plum Island Animal Disease Center » Foreign Animal Disease Research » Research » Research Project #428061

Research Project: Alternative Approaches for the Development of an Experimental African Swine Fever Virus (ASFV) Vaccine

Location: Foreign Animal Disease Research

Project Number: 8064-32000-060-05-I
Project Type: Interagency Reimbursable Agreement

Start Date: Jun 15, 2015
End Date: Mar 30, 2019

Objective:
Previous work at ARS, PIADC demonstrated that the deletion of specific African Swine Fever Virus (ASFV) genes produce significant attenuation of the virulent parental strains. This research project seeks to attenuate recombinant strains of the highly virulent Georgia ASFV (rG-ASFV) to produce deletions of the individual viral genes already shown to be responsible for producing attenuation of other virulent ASFV strains, and if attenuation is achieved, test the ability of those rG-ASFV to induce protection against the virulent challenge strain. Specific objectives include: 1. Development of recombinant Georgia ASFV (rG-ASFV) strains having deleted several of those genes previously identified to be involved in the production of attenuation of other virulent ASFV strains. 2. Development of ASFV subunit experimental vaccine using modified vaccine Ankara (MVA) virus as a delivery vector.

Approach:
1. The development of the recombinant Georgia ASFV strains will be accomplished through: a. Development of a second and third generations of recombinant Georgia ASFV strains. b. Evaluation of the residual virulence of second and third generation of rG-ASFV. c. Assessment induction of protective immunity of second and third generations of rG-ASFV. d. Assessment induction of protective immunity induced by rG-ASFVs against heterologous ASFV isolates. 2. The development of an ASFV subunit experimental vaccine using modified vaccine Ankara (MVA) virus as a delivery vector will be accomplished through: a. Design and construction of recombinant MVA (rMVA) co-expressing groups of selected ASFV proteins. b. Evaluation of the ASFV protein expression in cell cultures infected by rMVAs. c. Assessment of the induction of protective immunity of rMVA expressing ASFV proteins. d. The design of additional rMVAS.